We are changing our formulary list for 2025, moving to a biosimilar for a frequently prescribed medication, Humira®. This switch is part of our overall biosimilars strategy, an effort to look out for value, member choice, and cost savings for our clients and members.
For members new to therapy, Humira will no longer be on the Advantage formulary as of January 1, 2025. For existing users, it will not be on the Advantage formulary as of July 1, 2025. Humira will also not be a preferred product on the Preferred formulary as of July 1.
There are many benefits to using biosimilars:
- They have no clinically meaningful difference from their reference products and may be a safe and effective treatment option that may reduce plan and member costs.
- Moving to biosimilars allows members to choose, in conjunction with their prescribing doctor, which biosimilar product best meets their healthcare needs.
To learn more about MaxorPlus, please visit https://www.maxor.com/maxorplus/.
